论文信息 - A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC). - 字舞流文

A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC).

S. Tickoo | M. Milowsky | D. Bajorin | A. Regazzi | M. Milowsky | N. Ishill | D. Gallagher | S. Gerst | A. Trout | D. Gallagher | David J. Gallagher